Roxadustat

Drug Profile

Roxadustat

Alternative Names: ASP 1517; FG 4592

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator FibroGen
  • Developer Astellas Pharma; AstraZeneca; FibroGen
  • Class Amides; Antianaemics; Carboxylic acids; Isoquinolines; Small molecules
  • Mechanism of Action Basic helix loop helix transcription factor modulators; Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia
  • Discontinued Sickle cell anaemia

Most Recent Events

  • 08 Dec 2016 Astellas Pharma and FibroGen plan a phase III trial for Anaemia (in non-dialysis chronic kidney disease patients) in Japan (PO) (NCT02988973)
  • 13 Nov 2016 Astellas Pharma and FibroGen plan a phase III trial for Anaemia (in non-dialysis chronic kidney disease patients) in Japan (PO) (NCT02964936)
  • 11 Nov 2016 Astellas Pharma and FibroGen plan a phase I pharmacokinetics trial in United Kingdom and Germany (PO) (NCT02965040)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top